ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) today announced the signing of a Memorandum of Understanding with the University of Texas Health Science Center at San Antonio to collaborate on research to optimize the CyPath® diagnostic assay for lung cancer.
“UT Health Science Center in San Antonio is a world-class biomedical research and education institution with a proven track record of turning scientific research into clinical practice,” said Biomoda CEO Maria Zannes. “We will benefit from the Health Science Center’s extensive resources for our ongoing optimization work in preparation for the multi-site pivotal trial. We also intend to tap into the economic grant programs and research funding afforded by this initiative.”
Health Science Center Vice President for Research Dr. Brian Herman said, “We will be working with Biomoda to bring its cancer diagnostic tests to the front end of medical treatment in order to use medical expertise and resources as efficiently and effectively as possible.”
“Our research will progress more quickly and our science will be strengthened by this initiative,” said Biomoda President John Cousins. “Biomoda is focused on optimization of its assay to include automating sample reading through flow cytometry and refining the use of fluorescent microscopy to identify cancer cell types and pre-cancerous cells. The Health Science Center not only will greatly assist us with the science, but we believe the partnership has the potential to create jobs and economic growth for the region.”
About Biomoda
Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
About UT Health Science Center at San Antonio
One of the country’s leading health sciences universities, The University of Texas Health Science Center at San Antonio ranks in the top 3% of all institutions worldwide receiving federal funding. The Health Science Center performs biomedical research focused on accelerating, facilitating, and increasing the discovery, development, and dissemination of biomedical solutions that improve the quality of life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, which are described from time to time in the Company’s filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.